Clinical trials: Risks of Adverse Events After Cardiac Surgery
- Condition Risks of Adverse Events After Cardiac Surgery
- Funder type Industry (pharma, biotech, devices)
Cardiac Surgery
QPI-1002 Phase 3 for Prevention of Major Adverse Kidney Events (MAKE) in Subjects at High Risk for AKI Following Cardiac Surgery
This trial is designed to evaluate QPI-1002 versus placebo for the prevention of Major Adverse Kidney Events (MAKE) in subjects at high risk for acute kidney injury following cardiac surgery.
- Trial name
- NCT03510897
- Testing
- teprasiran
- Where
- 104 sites in United States, Australia and 9 more
- Volunteers
- 1,043 people
- Sponsor
- Quark Pharmaceuticals